Webinar: Pharmaceutical R&D Value Measurement
Sponsored by: Deloitte
Focused on:
Date: 15th November
Days old: 4831
Time: 3PM London / 10AM New York
Return on R&D Investment
Last year, Deloitte developed a performance snapshot of the top 12 research-based pharmaceutical companies on 1 January 2010 to baseline R&D IRR. Using proprietary methodology, Deloitte calculated the IRR for each of the 12 companies using Thomson Reuters data assets and publicly available data sources.
One year on, we see some significant movements in IRR, highlighting that absolute or static IRR measures alone do not tell the full story of R&D returns.
To be successful, companies need to demonstrate over a multi-year timeframe a consistent level of pipeline momentum (i.e. a continuous supply of new products into the late stage pipeline and successful commercialisation of products from the late stage pipeline).
In this webinar, Deloitte's R&D experts will cover:
• The pressures facing R&D and why R&D is under more pressure than ever to earn its investment
• The latest results from Deloitte's IRR peer benchmarking study, including the importance of dynamic IRR measures
• The key value levers that drive R&D performance
• What pharmaceutical companies are doing to rise to the R&D productivity challenge
Whitepapers
Presented by
Julian Remnant,
Deloitte, Life Sciences R&D Advisory Lead Partner (Europe).
Julian is a Partner in Deloitte's Life Sciences team based in London where he heads up our R&D advisory services practice across Europe. He has 20 years of consulting experience and has worked extensively within the global pharmaceutical industry and in secondary healthcare.
Julian specialises in the planning and delivery of strategies to raise return on the investment (ROI) in pharmaceutical R&D. He has led value improvement programs within development at pharmaceutical majors, biotechnology companies, contract research organisations and site management organisations.
Julian is the author of Deloitte's study "Is R&D Earning Its Investment?" This research explores the industry's R&D ROI performance using an empirical methodology developed by Deloitte. The findings of the Deloitte study were featured in the Financial Times and Pharma Times. Julian also writes regularly for SCRIP Clinical Research on value realisation from R&D.
Dan Baker,
Deloitte, Director, Audit and Advisory.
Dan is a life sciences specialist, based within our UK Audit practice. He serves our largest and most complex clients, including a number of large listed businesses, including London Stock Exchange and NASDAQ groups, in addition to small entrepreneurial start-ups.
He has a life sciences education and is a key member of our Healthcare & Life Sciences team. He spends the majority of his time working in the sector with a number of large groups in both an audit and advisory capacity.
Hugo Cervantes,
Deloitte, Life Sciences R&D Consultant.
Hugo is as a Manager in Deloitte Consulting's Life Sciences practice in the United Kingdom. He has approximately 10 years experience in providing professional services to the life sciences sector with the goal of increasing return on investment (ROI) in R&D.
Hugo has managed various value improvement projects in R&D clinical development, spanning eClinical (primarily EDC, CDMS, data warehouses), Business Process Outsourcing (data management, stats) to process redesign - within top pharmaceutical companies, biotechnology companies and CROs. Hugo specialises in clinical development strategy, clinical operations, R&D business process outsourcing and IT strategy. Hugo has contributed to Deloitte's R&D Value Measurement programme.
Download Slides
Please login to download the slidesKey Learning Objectives
- Understand the pressures facing R&D and why R&D is under pressure to earn its investment
- The latest results from Deloitte's IRR peer benchmarking study, including the importance of dynamic returns measures
- Understand the value levers that drive R&D performance
- Understand what other companies are doing to rise to the R&D productivity challenge
Audience
- CEO/President/Chairman/Executive Director
- CFO
- CIO/CTO/CISO/CSO
- Laboratory / R&D Management
- Other R&D
- R&D Management
- Heads of R&D Finance
- R&D Finance personnel